Print

Gilead Sciences, Inc. (GILD) Release: Vaginal Gel Cuts HIV Infections While Blocking Herpes  
7/26/2010 3:37:30 PM

July 19 (Bloomberg) -- A vaginal gel containing Gilead Sciences Inc.’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
//-->